Published in J Med Microbiol on February 01, 2005
Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis (2006) 7.64
Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J Clin Microbiol (2008) 3.15
Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J Clin Microbiol (2007) 2.77
Colitis due to Clostridium difficile toxins: underdiagnosed, highly virulent, and nosocomial. Proc (Bayl Univ Med Cent) (2006) 2.26
Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J Clin Microbiol (2007) 2.05
Evaluation of diagnostic tests for Clostridium difficile infection. J Clin Microbiol (2009) 1.92
Is a two-step glutamate dehyrogenase antigen-cytotoxicity neutralization assay algorithm superior to the premier toxin A and B enzyme immunoassay for laboratory detection of Clostridium difficile? J Clin Microbiol (2008) 1.88
Rapid and sensitive loop-mediated isothermal amplification test for Clostridium difficile detection challenges cytotoxin B cell test and culture as gold standard. J Clin Microbiol (2010) 1.85
Evaluation of a loop-mediated isothermal amplification assay for diagnosis of Clostridium difficile infections. J Clin Microbiol (2011) 1.62
Evaluation of the Cepheid Xpert Clostridium difficile Epi assay for diagnosis of Clostridium difficile infection and typing of the NAP1 strain at a cancer hospital. J Clin Microbiol (2010) 1.49
Evaluation of a new commercial TaqMan PCR assay for direct detection of the clostridium difficile toxin B gene in clinical stool specimens. J Clin Microbiol (2009) 1.41
Algorithm combining toxin immunoassay and stool culture for diagnosis of Clostridium difficile infection. J Clin Microbiol (2009) 1.34
Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile. J Clin Microbiol (2009) 1.33
Comparison of a rapid molecular method, the BD GeneOhm Cdiff assay, to the most frequently used laboratory tests for detection of toxin-producing Clostridium difficile in diarrheal feces. J Clin Microbiol (2009) 1.30
Evaluation of a chromogenic culture medium for isolation of Clostridium difficile within 24 hours. J Clin Microbiol (2010) 1.11
Bench-to-bedside review: Clostridium difficile colitis. Crit Care (2008) 1.08
The mosaic nature of intergenic 16S-23S rRNA spacer regions suggests rRNA operon copy number variation in Clostridium difficile strains. Appl Environ Microbiol (2006) 1.08
Rapid and simple method for detecting the toxin B gene of Clostridium difficile in stool specimens by loop-mediated isothermal amplification. J Clin Microbiol (2005) 1.07
Outcomes in patients tested for Clostridium difficile toxins. Diagn Microbiol Infect Dis (2012) 1.03
Rapid stool-based diagnosis of Clostridium difficile infection by real-time PCR in a children's hospital. J Clin Microbiol (2011) 1.01
Molecular techniques for diagnosis of Clostridium difficile infection: systematic review and meta-analysis. Mayo Clin Proc (2012) 0.99
Evaluation of two rapid immunochromatography tests for the detection of Clostridium difficile toxins. Dig Dis Sci (2007) 0.99
Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol (2010) 0.97
Rapid diagnosis of Clostridium difficile infection by multiplex real-time PCR. Eur J Clin Microbiol Infect Dis (2011) 0.96
Role of fecal Clostridium difficile load in discrepancies between toxin tests and PCR: is quantitation the next step in C. difficile testing? Eur J Clin Microbiol Infect Dis (2012) 0.96
The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge. Zoonoses Public Health (2010) 0.93
Evaluation of four different diagnostic tests to detect Clostridium difficile in piglets. J Clin Microbiol (2011) 0.87
Comparison of BD GeneOhm Cdiff and Seegene Seeplex ACE PCR assays using toxigenic Clostridium difficile culture for direct detection of tcdB from stool specimens. J Clin Microbiol (2012) 0.85
Evaluation of cycloserine-cefoxitin fructose agar (CCFA), CCFA with horse blood and taurocholate, and cycloserine-cefoxitin mannitol broth with taurocholate and lysozyme for recovery of Clostridium difficile isolates from fecal samples. J Clin Microbiol (2013) 0.85
Correlation between Clostridium difficile bacterial load, commercial real-time PCR cycle thresholds, and results of diagnostic tests based on enzyme immunoassay and cell culture cytotoxicity assay. J Clin Microbiol (2013) 0.84
Sensitive quantification of Clostridium perfringens in human feces by quantitative real-time PCR targeting alpha-toxin and enterotoxin genes. BMC Microbiol (2015) 0.83
A Clostridium difficile infection "intervention": change in toxin assay results in fewer C difficile infection cases without changes in patient outcomes. Am J Infect Control (2011) 0.83
Performance of chromID Clostridium difficile agar compared with BBL C. difficile selective agar for detection of C. difficile in stool specimens. Ann Lab Med (2014) 0.81
Comparison of a frozen human foreskin fibroblast cell assay to an enzyme immunoassay and toxigenic culture for the detection of toxigenic Clostridium difficile. Diagn Microbiol Infect Dis (2012) 0.80
Clostridium difficile outbreaks. Can J Infect Dis Med Microbiol (2007) 0.78
Development of a microarray for identification of pathogenic Clostridium spp. Diagn Microbiol Infect Dis (2009) 0.78
Economic evaluation of laboratory testing strategies for hospital-associated Clostridium difficile infection. J Clin Microbiol (2013) 0.78
Evaluation of multiplex PCR with enhanced spore germination for detection of Clostridium difficile from stool samples of the hospitalized patients. Biomed Res Int (2013) 0.76
A Decade of Development of Chromogenic Culture Media for Clinical Microbiology in an Era of Molecular Diagnostics. Clin Microbiol Rev (2017) 0.75
Diagnostic algorithm using a sensitive broth culture method for detection of Clostridium difficile toxin from stool samples. Can J Infect Dis Med Microbiol (2009) 0.75
Use of culture- and ELISA-based toxin assay for detecting Clostridium Difficile, a neglected pathogen: A single-center study from a tertiary care setting. J Lab Physicians (2017) 0.75
Hand hygiene among physicians: performance, beliefs, and perceptions. Ann Intern Med (2004) 4.63
Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS (2003) 4.43
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med (2010) 2.17
Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS (2010) 1.93
Distribution of nocardia species in clinical samples and their routine rapid identification in the laboratory. J Clin Microbiol (2005) 1.60
Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS (2011) 1.47
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother (2003) 1.31
HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clin Infect Dis (2012) 1.28
HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood (2011) 1.25
Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. Antivir Ther (2012) 1.19
Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis (2005) 1.18
Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J Infect (2006) 1.18
Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort study. J Acquir Immune Defic Syndr (2013) 1.18
Evaluation of Oxoid combination discs for detection of extended-spectrum beta-lactamases. J Antimicrob Chemother (2003) 1.17
Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours. PLoS One (2008) 1.17
Brevibacterium lutescens sp. nov., from human and environmental samples. Int J Syst Evol Microbiol (2003) 1.15
Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS (2006) 1.11
Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patients. J Med Virol (2007) 1.08
Biochemical and susceptibility tests useful for identification of nonfermenting gram-negative rods. J Clin Microbiol (2002) 1.06
Human CD90 identifies Th17/Tc17 T cell subsets that are depleted in HIV-infected patients. J Immunol (2011) 1.02
Bacteremia due to a novel Microbacterium species in a patient with leukemia and description of Microbacterium paraoxydans sp. nov. J Clin Microbiol (2003) 1.02
E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure. AIDS (2012) 1.00
Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS (2009) 1.00
Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine (2005) 0.99
Description of Wautersiella falsenii gen. nov., sp. nov., to accommodate clinical isolates phenotypically resembling members of the genera Chryseobacterium and Empedobacter. Int J Syst Evol Microbiol (2006) 0.99
Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors. AIDS (2006) 0.98
Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. AIDS (2011) 0.97
In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. Int J Antimicrob Agents (2010) 0.96
Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4). Int J Epidemiol (2014) 0.96
Burden of HIV disease and comorbidities on the chances of maintaining employment in the era of sustained combined antiretoviral therapies use. AIDS (2012) 0.95
Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Antivir Ther (2002) 0.95
Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients. AIDS (2007) 0.95
Endocarditis due to Neisseria bacilliformis in a patient with a bicuspid aortic valve. J Clin Microbiol (2009) 0.95
Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients. AIDS (2008) 0.95
The type 1 cannabinoid receptor is highly expressed in embryonic cortical projection neurons and negatively regulates neurite growth in vitro. Eur J Neurosci (2008) 0.94
The role of diacylglycerol lipase in constitutive and angiotensin AT1 receptor-stimulated cannabinoid CB1 receptor activity. J Biol Chem (2007) 0.94
Clathrin-dependent APP endocytosis and Abeta secretion are highly sensitive to the level of plasma membrane cholesterol. Biochim Biophys Acta (2010) 0.93
Incidence and virulence determinants of verocytotoxin-producing Escherichia coli infections in the Brussels-Capital Region, Belgium, in 2008-2010. J Clin Microbiol (2012) 0.93
Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug. J Antimicrob Chemother (2009) 0.93
Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis (2013) 0.91
Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. J Antimicrob Chemother (2011) 0.91
Identification of a novel Brevibacterium species isolated from humans and description of Brevibacterium sanguinis sp. nov. J Clin Microbiol (2004) 0.90
Study of genotypes and virB4 secretion gene of Bartonella henselae strains from patients with clinically defined cat scratch disease. J Clin Microbiol (2004) 0.89
Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy. AIDS (2006) 0.89
Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases. J Med Virol (2008) 0.89
Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. AIDS (2010) 0.89
Highly active antiretroviral therapy corrects hematopoiesis in HIV-1 infected patients: interest for peripheral blood stem cell-based gene therapy. AIDS (2003) 0.88
Description of Chryseobacterium anthropi sp. nov. to accommodate clinical isolates biochemically similar to Kaistella koreensis and Chryseobacterium haifense, proposal to reclassify Kaistella koreensis as Chryseobacterium koreense comb. nov. and emended description of the genus Chryseobacterium. Int J Syst Evol Microbiol (2009) 0.87
Annexin-A6 presents two modes of association with phospholipid membranes. A combined QCM-D, AFM and cryo-TEM study. J Struct Biol (2009) 0.87
Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort. AIDS (2014) 0.87
Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years. AIDS (2011) 0.85
Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali. Antivir Ther (2007) 0.85
Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients. J Med Virol (2005) 0.85
Ultrasonography in chondrocalcinosis. Joint Bone Spine (2010) 0.84
Toxin A detection on Clostridium difficile colonies from 24-h cultures. Clin Microbiol Infect (1996) 0.84
Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. AIDS (2013) 0.83
Specific adaptive humoral response against a gp41 motif inhibits CD4 T-cell sensitivity to NK lysis during HIV-1 infection. AIDS (2006) 0.83
Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1. J Med Virol (2012) 0.83
Crystal structure and immunological properties of the first annexin from Schistosoma mansoni: insights into the structural integrity of the schistosomal tegument. FEBS J (2014) 0.83
Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies. J Antimicrob Chemother (2013) 0.83
Psychrobacter isolates of human origin, other than Psychrobacter phenylpyruvicus, are predominantly Psychrobacter faecalis and Psychrobacter pulmonis, with emended description of P. faecalis. Int J Syst Evol Microbiol (2011) 0.83
Isolates belonging to CDC group II-i belong predominantly to Sphingobacterium mizutaii Yabuuchi et al. 1983: emended descriptions of S. mizutaii and of the genus Sphingobacterium. Int J Syst Evol Microbiol (2011) 0.83
Pitfalls of HIV genotypic tropism testing after treatment interruption. J Antimicrob Chemother (2012) 0.82
Activation-dependent subcellular distribution patterns of CB1 cannabinoid receptors in the rat forebrain. Cereb Cortex (2012) 0.81
Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs. J Clin Microbiol (2003) 0.80
Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments. AIDS (2014) 0.80
Hyposplenism revealed by Plasmodium malariae infection. Malar J (2013) 0.80
Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism. J Med Virol (2012) 0.80
The LMW surface-layer proteins of Clostridium difficile PCR ribotypes 027 and 001 share common immunogenic properties. J Med Microbiol (2011) 0.80
Lack of TGF-β production by hepatitis C virus-specific T cells during HCV acute phase is associated with HCV clearance in HIV coinfection. J Hepatol (2012) 0.79
Ripple formation in unilamellar-supported lipid bilayer revealed by FRAPP. Eur Phys J E Soft Matter (2013) 0.79
Mycobacterium mucogenicum sepsis in an immunocompetent patient. J Infect (2006) 0.79
Histidine decarboxylase in Enterobacteriaceae revisited. J Clin Microbiol (2004) 0.79
Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy. Antivir Ther (2012) 0.79
Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma. J Acquir Immune Defic Syndr (2009) 0.79
Safety of active implantable devices during MRI examinations: a finite element analysis of an implantable pump. IEEE Trans Biomed Eng (2007) 0.78
Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response. AIDS Res Hum Retroviruses (2014) 0.78
Divalent cations and redox conditions regulate the molecular structure and function of visinin-like protein-1. PLoS One (2011) 0.78
SDAR: a practical tool for graphical analysis of two-dimensional data. BMC Bioinformatics (2012) 0.78
Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. AIDS (2008) 0.78
Description of Acidovorax wautersii sp. nov. to accommodate clinical isolates and an environmental isolate, most closely related to Acidovorax avenae. Int J Syst Evol Microbiol (2012) 0.78
Insights into the membrane interactions of the saposin-like proteins Na-SLP-1 and Ac-SLP-1 from human and dog hookworm. PLoS One (2011) 0.78
E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations. Antiviral Res (2011) 0.77
Axonal targeting of the 5-HT1B serotonin receptor relies on structure-specific constitutive activation. Traffic (2011) 0.77
Chryseobacterium hominis sp. nov., to accommodate clinical isolates biochemically similar to CDC groups II-h and II-c. Int J Syst Evol Microbiol (2007) 0.77
Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother (2006) 0.76
Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B. J Antimicrob Chemother (2013) 0.76